December 8, 2010

Effects of ubiquinol on influenza virus infection in mice in collaboration
with University of Toyama

Kaneka Corporation (headquarters: Osaka; President: Mr. Kimikazu Sugawara) announced that they
confirmed the effect of ubiquinol on type A influenza virus infection in mice in collaboration with
Prof. Toshimitsu Hayashi, University of Toyama.

Mice were intranasally infected with influenza virus (H1N1 subtype) and ubiquinol was
administered from 7 days before the infection until 3 or 7 days after the infection. The effect of
ubiquinol was assessed by examining: 1) Virus yield in the bronchoalveolar lavage fluid (BALF) and
the lungs, 2) The antibody titers in the BALF and the blood sera.

As a result, the virus yield was suppressed in the ubiquinol-treated group which showed 19-24% and
49-52% of the control group in the BALF and the lungs, respectively, with statistically significant
changes (See Fig 1, Virus yield in the BALF). Oseltamivir (Tamiflu) suppressed the antibody titer
for the virus, but ubiquinol kept the antibody titer level similar to the control group. In addition, the
combination effect was confirmed when ubiquinol is co-administered with Probiotics.

Ubiquinol was considered to activate an immune response and suppressed the growth of the
influenza virus in this animal study, since it is suggested that ubiquinol did not have the direct
anti-viral effect. The effect of ubiquinol on influenza virus infection was demonstrated for the first
time and its results are in preparation for publication in the near future.